I had a scare that turned out not to be pancreatitis, and the useful thing I took from it was how specific the presentation actually is.
The narrow version of the question is what the pooled safety data actually shows for this class, as opposed to what the label warning implies.
Tell me what I have not thought of.
sarah.morrison said:I had a scare that turned out not to be pancreatitis, and the useful thing I took from it was how specific the presentation actually is.
Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 11. Went to the ER — they checked lipase and amylase, both normal. Turned out to be a gallstone.
But I'm glad I went. The risk of pancreatitis, while small (<0.5%), is real. Don't try to tough out severe abdominal pain on a GLP-1 agonist. Get checked.
julia.endo said:Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 11.
Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk. All readings have been normal:
- Baseline: 43 U/L
- Month 3: 41 U/L
- Month 6: 31 U/L
- Month 9: 43 U/L
Normal range is 0-160 U/L. While clinical pancreatitis is rare (<0.5%), I find peace of mind in regular monitoring. Worth asking your doctor about if you're on a GLP-1 long-term.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultssarah.morrison said:I had a scare that turned out not to be pancreatitis, and the useful thing I took from it was how specific the presentation actually is.
Second this. Posting only so the count is not one.
Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.